Results 101 to 110 of about 7,983,647 (299)

Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer [PDF]

, 2013
Background: Preoperative radiochemotherapy (RCT) with 5-FU or capecitabine is the standard of care for patients with locally advanced rectal cancer (LARC). Preoperative RCT achieves pathological complete response rates (pCR) of 10-15%.
Erik Engel, Engel, Erik, Jürgen Dunst, Florian Würschmidt, Kathrin Dellas, Arnold, Dirk, Dirk Arnold, Michael Richter, Richter, Michael, Rödel, Claus, Thomas Reese, Höhler, Thomas, Thomas Höhler, Claus Rödel, Dellas, Kathrin, Reese, Thomas, Wagner, Wolfgang, Dunst, Jürgen, Würschmidt, Florian, Wolfgang Wagner   +19 more
core   +1 more source

Castration‐resistant prostate cancer cells are addicted to the high activity of cyclin‐dependent kinase 2

Molecular Oncology, EarlyView.
We show that emergence of castration‐resistant prostate (CRPC) is associated with significant upregulation of cyclins that positively regulate cyclin‐dependent kinase 2 (CDK2) and concomitant downregulation of CDK4 cyclins. This renders CRPC cells dependent on the high activity of CDK2, and CDK2 inhibitors synergistically sensitize CRPC cells to both ...
Joyeeta Chatterjee, Alessia Marin, Shivani Yalala, Harri M. Itkonen   +3 more
wiley   +1 more source

Partial FAK suppression promotes tumor growth, an effect reversed by macrophage p110δ PI3K inactivation

Molecular Oncology, EarlyView.
Partial inhibition of focal adhesion kinase (FAK) can paradoxically promote tumor growth, rather than simply producing a weaker antitumor effect than that observed with strong FAK suppression. In breast cancer and melanoma models, targeting p110δ PI3K, particularly in macrophages, counteracted these tumor‐promoting effects, highlighting the importance ...
Lydia Xenou, Niki Tzenaki, Anna Tsapara, Maria Tzardi, Evangelia A. Papakonstanti   +4 more
wiley   +1 more source

Predicting Pathological Response of Neoadjuvant Conversion Therapy for Hepatocellular Carcinoma Patients Using CT-Based Radiomics Model [PDF]

Haoxiang Wen,1,2,* Ruiming Liang,3,* Xiaofei Liu,4 Yang Yu,1 Shuirong Lin,1 Zimin Song,1 Yihao Huang,1 Xi Yu,1 Shuling Chen,5 Lili Chen,6 Baifeng Qian,1 Jingxian Shen,7 Han Xiao,8 Shunli Shen1 1Center of Hepato-Pancreatico-Biliary Surgery, The ...
Shen J, Lin S, Chen L, Qian B, Liu X, Wen H, Huang Y, Xiao H, Shen S, Chen S, Song Z, Yu X, Liang R, Yu Y   +13 more
core  

Profiling neoadjuvant therapy response in rectal cancer using meta‐analysis of publicly available transcriptomic RNA‐seq datasets

Molecular Oncology, EarlyView.
This study integrates publicly available transcriptomic datasets to identify molecular signatures associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. By analyzing a combination of multiple cohorts with bioinformatics approaches, we reveal biological pathways and immune‐related features that may improve ...
Aleksandra Stanojevic, Rafael Stroggilos, Mladen Marinkovic, Ana Djuric, Suzana Stojanovic‐Rundic, Radmila Jankovic, Sergi Castellvi‐Bel, Remond J.A. Fijneman, Antonia Vlahou, Jerome Zoidakis, Milena Cavic   +10 more
wiley   +1 more source

Probability of pathological complete response according to menopausal status and BMI category.

, 2013
Probability of pathological complete response according to menopausal status and BMI category.
Ke-Da Yu (166128), Sheng Chen (21971), Can-Ming Chen (314340), Ying Zhou (25031), Ruo-Ji Zhou (314341), Zhi-Ming Shao (87153)   +5 more
core   +1 more source

Predictive and prognostic biomarkers of Bacillus Calmette‐Guérin therapy failure in bladder cancer patients: A systematic review

Molecular Oncology, EarlyView.
High‐risk bladder cancer is typically treated with Bacillus Calmette‐Guérin (BCG), but 30–40% of patients relapse. No FDA‐ or CE‐approved biomarkers currently predict or prognosticate BCG failure. We systematically reviewed the literature and identified 72 eligible studies, revealing several promising biomarkers associated with BCG treatment response ...
Rui Ribeiro‐Pereira, Ana Teixeira‐Marques, Rui Freitas, João A Carvalho, Sara Monteiro‐Reis, Giorgio I. Russo, Rui Henrique, Carmen Jerónimo   +7 more
wiley   +1 more source

Effect of adjuvant chemotherapy on the oncological outcome of rectal cancer patients with pathological complete response

Background Locally advanced rectal cancer is typically treated using a combination of neoadjuvant chemoradiotherapy and total mesorectal resection. While achieving pathological complete response following neoadjuvant chemoradiotherapy has been recognized
Zhongxue Fu, Qican Deng, Xin Wu, Jianguo Yang, Yong Cheng   +4 more
core   +1 more source

The need for effective radiosentitizing agents: experience in patients with complete pathological response

, 2011
Chemoradiation therapy is now considered the preferred initial treatment strategy for distal rectal cancer because of the observation of better local disease control and significant tumor downstaging.
PEREZ, Rodrigo O., Angelita Habr-Gama, HABR-GAMA, Angelita, JULIAO, Guilherme P. Sao, GAMA-RODRIGUES, Joaquim, Rodrigo O. Perez, Igor Proscurshim, Guilherme P. São Julião, Joaquim Gama-Rodrigues, PROSCURSHIM, Igor   +9 more
core   +1 more source

Do not expect an endoluminal complete response to identify a pathologic complete response in rectal cancer!

Clinics
To examine the relationship between endoluminal and pathologic complete response after chemoradiotherapy for rectal cancer and identify predictors of a pathologic complete response.The anatomic pathology reports of 102 consecutive patients with rectal cancer who underwent neoadjuvant chemoradiotherapy followed by proctectomy between 2013 and 2017 were ...
Alexandre Gheller, Guilherme Inácio Bertoldo de Melo e Patriarca da Silva Neiva, Mario Nóbrega de Araújo Neto, Fernando Gonçalves Lyrio, Dunya Bachour Basílio, Marília Cristina Roda da Costa, Douglas Vieira Mourão, Paulo Gonçalves de Oliveira, João Batista de Sousa   +8 more
openaire   +3 more sources